CRISPR PATENT LANDSCAPE

January 2017

Intangible assets deserve closer scrutiny
Copyright

• Unless otherwise specified, all content included on this document, such as text, graphics, logos, button icons, images, audio and video clips, digital downloads, data compilations, and software, **including but not limited to IPStudies surveys**, is the property of IPStudies SARL and protected by international copyright laws.

• You agree not to copy, reproduce, duplicate, sell, resell, or exploit for any commercial purposes, any portion of this content.

• You may not re-use and/or extract part of this content outside of your legal entity, institutional or corporate environment without IPStudies’s express consent in writing.
Our team

Corinne LE BUHAN, PhD
ICT Expert
IP Strategy & Management

- Funded IPStudies in 2010 to help Swiss & EU high-tech SMEs develop and execute their IP valuation plans using the latest patent analytics tools and trends
- 15 years experience in IP strategy and management – former VP Knowledge Management of Nagravision-Kudelski Group, in charge with patents (200 families), standards, R&D collaborations, licensing and technical publications portfolios
- Teaches international licensing practices and IP strategy at IEEPI – EU Horizon2020 expert on Innovation in SMEs 2013-2015
- ICT Technology Expert for various licensing facilitators and aggregators in France, Germany and the US
- University postgraduate in management of innovation and intellectual property (University of Strasbourg, 2008), PhD in Communications Science (EPFL, 1998), MsC in Electrical Engineering (INSA Rennes, 1994)
- Experienced with Patbase, EPO/RegisterPlus, USPTO/PAIR
- International network of IP practitioners and licensing managers - Member LES, IEEE, AROPI, AAIEEPI

Fabien PALAZZOLI, PhD
Life Sciences Expert
Patent Analysis & Landscapes

- Joined IPStudies in 2013 to develop the IP analytics offering in life sciences & biotechnology
- 9+ years experience in technology transfers, patent mapping/landscaping and FTO-driven research intelligence for the French public sector and biotech SMEs - former IP analytics sales manager for FIST SA, the CNRS technology transfer office
- Author/co-author of 18 scientific and technical publications/communications, as well as one book chapter
- Life sciences patent analyst for various biotech/medtech SMEs in Switzerland and in Europe
- PhD in Life Sciences (Exploitation of patent information in a public research laboratory: identification of technological niches in bioproduction and gene therapy, University of Tours, 2011), MsC in Biotechnology and Law (University of Tours, 2007)
- Experienced with Orbit, Patbase, Intellixir, patent offices databases
- International network of patent information analysts
Table of contents

• Methodology
• Overall trends of the CRISPR patent database
  • Temporal distribution of patent filings (2002-2016)
  • Temporal distribution of patent filings by type of players (2002-2016)
  • World map of priority filings
  • Temporal distribution of priority filings (2002-2016)
  • World map of patent extensions
  • Main patent applicants/assignees
  • Temporal distribution of filings of applicants/assignees
  • Co-filings between applicants/assignees
• Breakdown of the CRISPR patent database
  • Breakdown by Claim coverage of patent families
    • Breakdown of the patent portfolio
    • Temporal distribution of filings
    • Positioning of applicants/assignees
  • Breakdown by Components
    • Breakdown of the patent portfolio
    • Temporal distribution of filings
    • Positioning of the applicants/assignees
  • Breakdown by Chimeric proteins
    • Breakdown of the patent portfolio
    • Temporal distribution of filings
    • Positioning of applicants/assignees
• Main forward cited patent families
• Appendices – licensing announcements, affiliation mapping of players present in the patent landscape
Temporal distribution of patent filings by type of players (2002-2016)

- 707 filings by institutional applicants/assignees (61.7%),
- 358 filings by industrial applicants/assignees (31.2%),
- 48 filings by individual inventors (4.2%),
- 33 co-filings between industrial applicants/assignees and institutional applicants/assignees (2.9%).
- The years 2015 and 2016 are not complete due to the delay of publication of 18 months in most jurisdictions.
Main patent applicants/assignees (≥ 7 patent families)

- Affiliates & subsidiaries have been gathered under their parent company (Danisco with DuPont...). Co-filings are counted for each co-owner: a patent application co-filed between the MIT, the Harvard University and the Broad Institute is counted once for each applicant.

- The patent portfolio of DuPont comprises historical patent families on CRISPR sequences dealing with the typing of bacterial strains, cultures with improved phage resistance and applications for preparing food.
Co-filings between applicants/assignees

The co-filing map shows the co-filings between applicants/assignees. The same type of link can be found when an assignment occurred between two players, giving the historical applicants as well as the new owners.
## License announcements – SAMPLE PAGE (4)

<table>
<thead>
<tr>
<th>Licensor</th>
<th>Scope</th>
<th>Licensee</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toolgen</td>
<td>Worldwide license &amp; sublicenses rights for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bioproduction. ToolGen retains its rights in broad areas including high throughput screening, diagnostics, bioproduction, plant biotechnology and gene/cell therapy.</td>
<td>Thermo Fisher Scientific</td>
<td>2015/03</td>
</tr>
<tr>
<td>DuPont</td>
<td>The cross-license enables Caribou to develop and utilize CRISPR-Cas technology for product development in multiple fields including human and animal therapeutics, diagnostics, industrial biotechnology, research tools, and certain agriculture segments. The DuPont license to Caribou includes rights to the Cas9-mediated genome editing intellectual property owned by Vilnius University and exclusively licensed to DuPont.</td>
<td>Caribou Biosciences</td>
<td>2015/10</td>
</tr>
<tr>
<td>Caribou Biosciences</td>
<td>Multi-faceted agreement includes the cross-licensing of key intellectual property, a research collaboration, and financial investments by DuPont in Caribou, a developer of CRISPR-Cas technologies.</td>
<td>DuPont</td>
<td>2015/10</td>
</tr>
<tr>
<td>Crispr Therapeutics</td>
<td>$105 million upfront—$75 million in cash, $30 million equity investment - future development, regulatory and sales milestones of up to $420 million for each of up to six CRISPR-Cas9-based treatments for which Vertex has agreed to license exclusive development rights. Royalties on future sales.</td>
<td>Vertex</td>
<td>2015/10</td>
</tr>
<tr>
<td>ERS Genomics</td>
<td>Non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development</td>
<td>Regeneron</td>
<td>2015/11</td>
</tr>
</tbody>
</table>
A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’ and ‘Human cell-subject’ and ‘CRISPR-Cas system’...).
Breakdown of the CRISPR patent database (2)

The 1146 patent families have been manually reviewed and classified

COMPONENTS

- CRISPR-associated protein
- Mutated Cas - nickase
- dCas
- Cas9
- mutated Cas9 - nickase
- dCas9
- Other Cas
- Other mutated Cas
- Cpf1
- gRNA
- sgRNA-chiRNA
- crRNA
- tracrRNA

- Nuclease-Nickase
- Meganuclease
- Integrase
- Recombinase
- Repressor-Activator
- Acetyltransferase
- Deacetylase
- Methyltransferase
- Demethylase
- Kinase
- Other catalytic domain
- Undefined catalytic domain

CHIMERIC PROTEINS

Chimeric nuclease

- Undefined nuclease
- ZF Nuclease
- Meganuclease
- TALE Nuclease
- RNA-Guided Nuclease
- Other chimeric nuclease

Other chimeric proteins

- A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’ and ‘Human cell-subject’ and ‘CRISPR-Cas system’...).
Breakdown by **Claim coverage of patent families**

Breakdown of the patent portfolio

---

**Applications**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Number of Patent Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genome Editing</td>
<td>931</td>
</tr>
<tr>
<td>Other application</td>
<td>179</td>
</tr>
<tr>
<td>Therapeutics/Diagnostics</td>
<td>283</td>
</tr>
<tr>
<td>Drug screening</td>
<td>447</td>
</tr>
<tr>
<td>Modified cell</td>
<td>539</td>
</tr>
<tr>
<td>Modified plant</td>
<td>472</td>
</tr>
<tr>
<td>Human cell-organism</td>
<td>399</td>
</tr>
<tr>
<td>Mammalian cell-organism</td>
<td>193</td>
</tr>
<tr>
<td>Other animal cell-organism</td>
<td>168</td>
</tr>
<tr>
<td>Plant cell-organism</td>
<td>148</td>
</tr>
<tr>
<td>Fungi/algae-yeast</td>
<td>239</td>
</tr>
<tr>
<td>Eukaryotic cell-organism</td>
<td>94</td>
</tr>
<tr>
<td>Prokaryotic cell</td>
<td>186</td>
</tr>
<tr>
<td>Other organism</td>
<td>125</td>
</tr>
<tr>
<td>Undefined</td>
<td>30</td>
</tr>
</tbody>
</table>

**Cell / Organism**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Number of Patent Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease</td>
<td>547</td>
</tr>
<tr>
<td>ZF Nuclease-ZFP</td>
<td>49</td>
</tr>
<tr>
<td>TALE Nuclease-TALE P</td>
<td>8</td>
</tr>
<tr>
<td>RNA-guide sequence</td>
<td>15</td>
</tr>
<tr>
<td>CRISPR-associated protein</td>
<td>225</td>
</tr>
<tr>
<td>CRISPR-Cas system</td>
<td>234</td>
</tr>
<tr>
<td>Other chimeric protein</td>
<td>58</td>
</tr>
<tr>
<td>Vector/Delivery</td>
<td>99</td>
</tr>
<tr>
<td>CRISPR sequence</td>
<td>247</td>
</tr>
</tbody>
</table>

**‘Covered molecular tools’**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Number of Patent Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copy only for COMPANY CORP</td>
<td>36</td>
</tr>
</tbody>
</table>

---
Breakdown by Chimeric proteins
Breakdown of the patent portfolio

Nucleases including chimeric nucleases

<table>
<thead>
<tr>
<th>Chimeric proteins</th>
<th>Number of patent families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undefined nuclease</td>
<td>195</td>
</tr>
<tr>
<td>ZF Nuclease</td>
<td>247</td>
</tr>
<tr>
<td>Meganuclease</td>
<td>109</td>
</tr>
<tr>
<td>TALE Nuclease</td>
<td>289</td>
</tr>
<tr>
<td>RNA-Guided Nuclease</td>
<td>1077</td>
</tr>
<tr>
<td>Other chimeric nuclease</td>
<td>34</td>
</tr>
<tr>
<td>Other chimeric protein</td>
<td>262</td>
</tr>
</tbody>
</table>
Further analytics for your specific needs with the online database

• Zoom on patent portfolios of specific applicants

• Zoom on patents filed in a country/region (US, EP, CN...), within a time period

• Zoom on patents covering an application, a dedicated technology, a specification or a functional subset

• Link to online patent office registers to review latest legal status
Access to the interactive “navigate, zoom, click and show patent” database

1. Geoconomics
2. Patent Details
3. Custom Field
4. Patent Search
Order

This is only a sample report with partial data. Our full offer includes:

• an **analysis of the patent landscape**, covering 1146 patent families, worldwide

• a **synthesis of IP strategy findings**, to visualize key trends in terms of patent applicants, collaboration networks, competitor technology positioning, key inventors and R&D white spaces out of the landscape

• an **on-line access to the 1146 patent families set**, so you can visualize, navigate, focus and extract the most relevant patent data according to your specific needs.

Contact us today for an offer at

sales@ipstudies.ch
+41 79 787 57 46